The goal of this clinical trial is to evaluate if a supplement called palmitoylethanolamide (PEA) is effective in reducing the pain in patients with chronic inflammatory pain conditions. The main question the trial aims to answer is if PEA works better at treating a patients pain and improving their function better than a placebo.
Participants will be divided into two equal groups and asked to take either PEA or a placebo for 8 weeks.

Start Date05 Aug 2024

Sponsor / Collaborator-

CTRI/2024/02/062402 / Not yet recruitingPhase 2

Pharmacokinetic Study of Palmitoylethanolamide (PEA) Extract in Healthy Human Volunteers. - Nil

Start Date16 Feb 2024

Sponsor / Collaborator

Tilman SA

100 Clinical Results associated with Palmidrol

100 Translational Medicine associated with Palmidrol

100 Patents (Medical) associated with Palmidrol

1,935

Literatures (Medical) associated with Palmidrol

01 Dec 2025·Current Allergy and Asthma Reports

Treatment of COVID-19 Associated Olfactory Dysfunction: A Systematic Review

Review

Author: Vanderbroek, Annabelle ; Clijsters, Marnick ; Moyaert, Mathilde ; Van Gerven, Laura ; Bischoff, Sabrina

PURPOSE OF REVIEWCOVID -19 associated olfactory dysfunction is widespread, yet effective treatment strategies remain unclear. This article aims to provide a comprehensive systematic review of therapeutic approaches and offers evidence-based recommendations for their clinical application.RECENT FINDINGSA living Cochrane review, with rigorous inclusion criteria, has so far included 2 studies with a low certainty of evidence. In this systematic review we list clinical data of 36 randomised controlled trials (RCTs) and non-randomised studies published between Jan 1, 2020 and Nov 19, 2023 regarding treatment options for COVID-19 associated olfactory dysfunction. Nine treatment groups were analysed, including olfactory training, local and systemic corticosteroids, platelet-rich plasma (PRP), calcium chelators, vitamin supplements including palmitoylethanolamide with luteolin, insulin, gabapentin and cerebrolysin. Primary objective was the effect of the studied treatments on the delta olfactory function score (OFS) for objective/psychophysical testing. Treatments such as PRP and calcium chelators demonstrated significant improvements on OFS, whereas olfactory training and corticosteroids did not show notable efficacy for COVID-19 associated olfactory dysfunction.

01 Jan 2025·International Journal of Cardiology

Right ventricular to pulmonary artery coupling in chronic thromboembolic pulmonary hypertension

Article

Author: Sørensen, Simon Grund ; Dudzinski, David M. ; Lyhne, Mads Dam ; Kirk, Mathilde Emilie ; Andersen, Asger ; Nielsen-Kudsk, Jens Erik ; Dudzinski, David M ; Hansen, Jacob Valentin ; Andersen, Stine ; Andersen, Mads Jønsson ; Mellemkjær, Søren ; Schultz, Jacob Gammelgaard ; Ilkjær, Lars Bo ; Merit, Victor Tang

BACKGROUNDChronic thromboembolic pulmonary hypertension (CTEPH) is characterized by increased pulmonary vascular resistance (PVR) and pressure and right ventricular (RV) dysfunction. We aimed to evaluate the correlation of RV to pulmonary artery coupling, measured as the tricuspid annular plane systolic excursion/pulmonary arterial systolic pressure (TAPSE/PASP) ratio, and invasive hemodynamic measurements, and to assess the changes in this ratio following CTEPH treatment.METHODSWe conducted a retrospective cohort study of CTEPH patients treated at Aarhus University Hospital with pulmonary angioplasty (BPA), pulmonary endarterectomy (PEA), and or medical therapy only. Patients underwent transthoracic echocardiography and right heart catheterization at baseline and follow-up. The primary endpoint was the association between TAPSE/PASP and PVR. Secondary endpoints included other hemodynamic and functional parameters.RESULTSThe study included 139 patients. Mean TAPSE/PASP at baseline was 0.22 [0.16, 0.29] mm/mmHg. An exponential decay correlation was found between TAPSE/PASP and PVR (correlation coefficient - 0.67, p < 0.001). The TAPSE/PASP ratio improved from 0.23 [0.18; 0.29] to 0.33 [0.26; 0.46] mm/mmHg, p < 0.0001, following BPA, and from 0.20 [0.15;0.27] to 0.35 [0.21;0.41] mm/mmHg, p = 0.0007 following PEA, indicating enhanced RV to pulmonary artery coupling.CONCLUSIONIn patients with CTEPH, the echocardiographic TAPSE/PASP ratio as a measure of RV-PA coupling correlates well with invasively measured pulmonary vascular resistance. The TAPSE/PASP ratio improved after BPA or PEA treatments suggesting a potential use for monitoring patient outcomes. Further prospective studies are warranted to establish the prognostic value of the TAPSE/PASP ratio and ability to guide treatment decisions.

01 Dec 2024·Medicine & Science in Sports & Exercise

Palmitoylethanolamide Does Not Affect Recovery from Exercise-Induced Muscle Damage in Healthy Males

Article

Author: DALLE, SEBASTIAAN ; SCHOUTEN, MONIEK ; BOGAERTS, STIJN ; VAN THIENEN, RUUD ; RAMAEKERS, MONIQUE ; COSTAMAGNA, DOMIZIANA ; PEERS, KOEN ; KOPPO, KATRIEN ; THOMIS, MARTINE

ABSTRACTIntroductionStrenuous eccentric exercise (EE) induces microstructural muscle damage, which decreases muscle performance. Palmitoylethanolamide (PEA) exerts analgesic and anti-inflammatory effects in clinical pain conditions and preclinical models of experimentally induced inflammation. This might hold clues for improved recovery from EE. Therefore, the current study evaluates the effect of PEA supplementation on functional and molecular responses to a single EE bout.MethodsEleven healthy male participants were included in a double-blind crossover study in which they received PEA (350 mg Levagen+) or placebo (maltodextrin) supplements, in a randomized order. In each experimental condition, participants performed an acute bout of EE (24 × 10 eccentric contractions of the knee extensors on an isokinetic dynamometer). At baseline, 24 (D1), 48 (D2), 72 (D3), and 120 h (D5) following EE, maximal voluntary contraction and jump height were measured. Blood samples were collected at baseline and on D1–D5, and muscle biopsies were collected at baseline and on D2. Perceived muscle soreness, sleep quality, and food intake were recorded daily.ResultsMuscle strength and jump height decreased following EE (up to ~40% and ~17%, respectively; Ptime < 0.05) in both conditions. This drop was accompanied by an increase in plasma creatine kinase and perceived muscle soreness (Ptime < 0.05). Furthermore, EE, but not PEA, increased the expression of the myogenic marker Pax7 and of the catabolic markers p-FoxO1-3a, p62, and LC3BII/I (Ptime < 0.05).ConclusionsPEA supplementation does not improve muscle soreness, muscle strength, and jump performance following a single EE bout. In addition, PEA supplementation had no effect on local or systemic markers of muscle damage, catabolism, or regeneration.

101

News (Medical) associated with Palmidrol

16 Sep 2024

·www.globenewswire.com

Clearmind Medicine Announces the Notice of an International Patent Application for Pioneering Ibogaine Combination Therapy

Innovative drug treatment developed in collaboration with SciSparc aims to enhance safety and efficacy in mental health and addiction care Vancouver, Canada, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the publication of an international patent application under the Patent Cooperation Treaty (“PCT”) for its pioneering combination therapy of Ibogaine and N-Acylethanolamines. Ibogaine, a key compound derived from the root of Tabernanthe iboga, a shrub native to West and Central Africa, has shown promise in human clinical trials for treating opioid use disorder (OUD), cocaine use disorder (CUD), and other substance use disorders (SUD). As a result, Ibogaine is considered a potentially effective anti-addiction agent. The patent application follows innovative developments from Clearmind’s successful collaboration with SciSparc Ltd. (Nasdaq: SPRC) (“SciSparc”), a clinical-stage specialty pharmaceutical company focused on treatments for central nervous system disorders. Together, the two companies are researching innovative combination therapies that integrate psychedelic compounds with the N-Acylethanolamines family, including Palmitoylethanolamide (PEA). Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine, commented: “The publication of this patent highlights Clearmind’s commitment to leadership in the psychedelics space through building a diverse patent portfolio, featuring technologies with varying timelines to market. Most importantly, we aim to provide safe and effective solutions for mental health conditions that currently have unmet needs. While treatments with Ibogaine are generally considered safe under proper medical supervision, there have been reports of fatalities or adverse events associated with the ingestion of iboga plant material or Ibogaine. We believe that combining Ibogaine with Palmitoylethanolamide will further enhance the efficacy and safety of this promising therapy.” About Clearmind Medicine Inc. Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements. The Company’s intellectual portfolio currently consists of nineteen patent families including 29 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio. Shares of Clearmind are listed for trading on Nasdaq under the symbol "CMND" and the Frankfurt Stock Exchange under the symbol “CWY0.” About SciSparc Ltd. SciSparc Ltd. (SPRC) is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company is currently engaged in the following drug development programs based on THC and/or non-psychoactive cannabidiol: SCI-110 for the treatment of Tourette Syndrome, for the treatment of Alzheimer's disease and agitation; and SCI-210 for the treatment of autism and status epilepticus. The Company also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seeds’ oil-based products on the Amazon.com Marketplace. For further information visit: https://www.clearmindmedicine.com or contact: Investor Relationsinvest@clearmindmedicine.com Telephone: (604) 260-1566US: CMND@crescendo-ir.com General Inquiries Info@Clearmindmedicine.com www.Clearmindmedicine.com Forward-Looking Statements: This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses Clearmind’s commitment to be a leader in the psychedelics space by creating a diverse patent portfolio, which contains various technologies with different times to market, but more importantly provides efficacious and safe solutions to various mental health conditions with unmet needs. The Company cannot assure that any patent will issue as a result of a pending patent application or, if issued, whether it will issue in a form that will be advantageous to the Company. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2023 filed with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.

16 Sep 2024

·www.biospace.com

SciSparc-Clearmind Medicine Collaboration Announces the Publication of an International Patent Application for Pioneering Ibogaine Combination Therapy

This innovative drug combination treatment focuses on boosting safety and efficacy in mental health and addiction care TEL AVIV, Israel, Sept. 16, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that as part of its ongoing collaboration with Clearmind Medicine Inc. (“Clearmind”) (Nasdaq: CMND) (FSE: CWY0), a biotechnology company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated mental health problems, the publication of an international patent application under the Patent Cooperation Treaty for the innovative combination of Ibogaine with N-Acylethanolamines. Ibogaine is the major constituent of the root of Tabernanthe iboga, a shrub commonly found in Western and Central Africa. Ibogaine use in human clinical trials suggests efficacy in the treatment of opioid use disorder, cocaine use disorder, and other substance use disorders, suggesting that Ibogaine is a potentially useful anti-addictive agent. Under this collaboration, the SciSparc and Clearmind are researching innovative combination therapies that integrate psychedelic molecules with the N-acylethanolamines family, including Palmitoylethanolamide. To date, thirteen patents related to this collaboration have been filed by Clearmind with the U.S. Patent and Trademark Office, as well as in several other global jurisdictions. About SciSparc Ltd. (Nasdaq: SPRC): SciSparc Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company is currently engaged in the following drug development programs based on THC and/or non-psychoactive cannabidiol: SCI-110 for the treatment of Tourette Syndrome, for the treatment of Alzheimer’s disease and agitation; and SCI-210 for the treatment of autism and status epilepticus. The Company also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seed oil-based products on Amazon Marketplace. About Clearmind Medicine Inc. Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements. The Company’s intellectual portfolio currently consists of nineteen patent families including 29 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio. Shares of Clearmind are listed for trading on Nasdaq under the symbol “CMND” and the Frankfurt Stock Exchange under the symbol “CWY0.” Forward-Looking Statements: This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, the Company is using forward looking statements when discussing ongoing collaborative research with Clearmind and potential benefits and advantages of Ibogaine. Since such statements deal with future events and are based on SciSparc’s current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of SciSparc could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in SciSparc’s Annual Report on Form 20-F filed with the SEC on April 1, 2024, and in subsequent filings with the U.S. Securities and Exchange Commission. Except as otherwise required by law, SciSparc disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise. Investor Contact: IR@scisparc.com Tel: +972-3-6167055

06 Sep 2024

·www.globenewswire.com

Clearmind Medicine Announces Publication of International Patent Application for Innovative MDMA-Based Combination Treatment

Pioneering Therapeutic Approach Aims to Enhance Safety and Efficacyin Mental Health and Addiction Treatments Vancouver, Canada, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the publication of an international patent application under the Patent Cooperation Treaty (“PCT”) for its innovative combination of 3,4-Methylenedioxymethamphetamine (MDMA) with N-Acylethanolamines. The patent application was filed as part of the Company's ongoing collaboration with SciSparc Ltd. (Nasdaq: SPRC) (“SciSparc”), a specialty pharmaceutical company in the clinical trial phase, dedicated to developing treatments for central nervous system disorders. Under this collaboration, the two companies are researching innovative combination therapies that integrate psychedelic molecules with the N-Acylethanolamines family, including Palmitoylethanolamide (PEA). To date, thirteen patents related to this collaboration have been filed with the U.S. Patent and Trademark Office, as well as in several other global jurisdictions. Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine, commented on the announcement: “The continued evolution of our patent portfolio reflects our strategic commitment to bringing innovative and effective treatments to market. While MDMA has shown promising clinical benefits as a standalone therapy, it also presents potential dose-limiting toxicities. Our unique combination of MDMA and PEA is designed to address critical safety concerns raised by the FDA regarding MDMA's safety profile. By combining MDMA with PEA, we aim to significantly reduce the MDMA dosage, thereby minimizing potential risks while maintaining therapeutic efficacy. We believe our strategy of combining psychedelic molecules and N-Acylethanolamines, could pave the way for a new era in the treatment of mental health disorders and addictions." About Clearmind Medicine Inc. Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements. The Company’s intellectual portfolio currently consists of nineteen patent families including 29 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio. Shares of Clearmind are listed for trading on Nasdaq under the symbol "CMND" and the Frankfurt Stock Exchange under the symbol “CWY0.” About SciSparc Ltd. SciSparc Ltd. (SPRC) is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company is currently engaged in the following drug development programs based on THC and/or non-psychoactive cannabidiol: SCI-110 for the treatment of Tourette Syndrome, for the treatment of Alzheimer's disease and agitation; and SCI-210 for the treatment of autism and status epilepticus. The Company also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seeds’ oil-based products on the Amazon.com Marketplace. For further information visit: https://www.clearmindmedicine.com or contact: Investor Relationsinvest@clearmindmedicine.com Telephone: (604) 260-1566US: CMND@crescendo-ir.com General Inquiries Info@Clearmindmedicine.com www.Clearmindmedicine.com Forward-Looking Statements: This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses how its patent portfolio signifies that its strategy and commitment to bring innovative treatments that are both effective and safe is proving itself and paving the way for a new era in the treatment of mental health disorders and addictions. The Company cannot assure that any patent will issue as a result of a pending patent application or, if issued, whether it will issue in a form that will be advantageous to the Company. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2023 filed with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.

100 Deals associated with Palmidrol

External Link

KEGG	Wiki	ATC	Drug Bank
D08328	Palmidrol	J	DB14043

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Respiratory Tract Infections	-	-	-

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Chronic musculoskeletal pain	Phase 2	CA	Quantum Biopharma Ltd.	19 Jan 2023
Chronic musculoskeletal pain	Phase 2	US	Quantum Biopharma Ltd.	19 Jan 2023
Chronic Pain	Phase 2	US	Quantum Biopharma Ltd.	19 Jan 2023
Chronic Pain	Phase 2	CA	Quantum Biopharma Ltd.	19 Jan 2023
Medium Chain Acyl CoA Dehydrogenase Deficiency	Phase 2	CA	Quantum Biopharma Ltd.	19 Jan 2023
Medium Chain Acyl CoA Dehydrogenase Deficiency	Phase 2	US	Quantum Biopharma Ltd.	19 Jan 2023
COVID-19	Phase 2	US	Quantum Biopharma Ltd.	14 Dec 2020
Idiopathic mast cell activation syndrome	Phase 2	-	Quantum Biopharma Ltd.	-
Inflammation	Phase 1	US	Quantum Biopharma Ltd.	-
Tourette Syndrome	Discovery	US	SciSparc Ltd.	01 Feb 2017

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASCO2023	Not Applicable	Extensive stage Small Cell Lung Cancer First line	-	Trilaciclib + PEA	(pncixacpla) = jbsuinssmz xpmjlnvoli (abpcsmvvrb )	Positive	31 May 2023
				PEA	(pncixacpla) = qtfdguiilp xpmjlnvoli (abpcsmvvrb )
ESMO2022	Not Applicable	Inflammation	-	Palmitoylethanolamide	viyhkprpui(abtbvswjid) = qckpgdjezl sjgyeztnau (zwxjwhgdpm )	-	10 Sep 2022
				Doxorubicin and trastuzumab	viyhkprpui(abtbvswjid) = bsarbityap sjgyeztnau (zwxjwhgdpm )
ESC2021	Not Applicable	-	-	Palmitoylethanolamide combined with polydatin	sydwgqjinc(wiegoxeixw) = ljsnbqebia ztngckoowi (phgxtzjeph )	-	29 Jun 2021
				palmitoylethanolamide	sydwgqjinc(wiegoxeixw) = nsqfcgemhs ztngckoowi (phgxtzjeph )
NCT03066193 (CTgov)	Phase 2	Tourette Syndrome	17	Palmitoylethanolamide+Dronabinol	hfkfwpnzyd(moonqyhokg) = noeamscxxr gzotqyryeb (cysycykfnw, nghlrglssm - djugvpnrfi) View more	-	19 Dec 2019
Pubmed \| J Psychiatr Res	Not Applicable	Autistic Disorder	-	Risperidone + Palmitoylethanolamide	wuhghfscxr(javannxmoe): Cohen's d = 0.94 (95% CI, 0.41 - 1.46), P-Value = 0.001	-	01 Aug 2018
				Risperidone + Placebo
ISRCTN72647928 (Pubmed \| Invest Ophthalmol Vis Sci)	Not Applicable	Hypertension	40	Palmitoylethanolamide 300 mg	hhttimfbja(qyxhxnitdu) = xyzquhncvv iwfqifeahw (sdujdveoxv ) View more	Positive	01 Feb 2013
				Placebo	hhttimfbja(qyxhxnitdu) = kmadkjcafi iwfqifeahw (sdujdveoxv ) View more
ISRCTN72647928 (ARVO2012)	Not Applicable	Hypertension	40	Palmitoylethanolamide	(vmqtbxukzm) = no side effects during the treatment period were observed dewfiudtfi (yrcuhdoton )	-	01 Mar 2012
				Placebo

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis